Brokerages Set Omnicell, Inc. (NASDAQ:OMCL) Price Target at $57.86

Omnicell, Inc. (NASDAQ:OMCL) has earned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $57.8571.

A number of brokerages have issued reports on OMCL. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Zacks Research raised shares of Omnicell from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Wells Fargo & Company cut their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 target price (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Finally, Weiss Ratings raised Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th.

Omnicell Price Performance

OMCL opened at $32.23 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of 38.37, a P/E/G ratio of 0.81 and a beta of 0.97. The firm’s fifty day moving average price is $37.24 and its two-hundred day moving average price is $38.79. Omnicell has a 1 year low of $29.06 and a 1 year high of $55.00.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The company had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. During the same quarter in the prior year, the company posted $0.45 earnings per share. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, analysts anticipate that Omnicell will post 1.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of Omnicell during the 2nd quarter worth $313,044,000. Dimensional Fund Advisors LP grew its position in Omnicell by 6.0% during the first quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock valued at $81,791,000 after buying an additional 137,834 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its holdings in Omnicell by 2.0% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock worth $47,095,000 after buying an additional 27,497 shares during the last quarter. Bank of America Corp DE increased its holdings in Omnicell by 31.3% during the first quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock worth $19,390,000 after buying an additional 138,537 shares during the last quarter. Finally, First Light Asset Management LLC bought a new stake in Omnicell in the first quarter worth about $16,351,000. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.